/
Oncology
T-Cell Acute Lymphoblastic Leukemia
28
Pipeline Programs↗
16
Active Trials↗
24
Companies Involved↗
T-cell acute lymphoblastic leukemia is an emerging landscape with 28 programs across 24 companies. The most active players are Essen Biotech, Beam Therapeutics. 8 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 14
Phase 216
Phase 38
Approved
No programs
Analysis
Modality Breakdown
70%
Small molecule
19 of 27 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 27 classified programs, each share of the total. Modality classified for 100% of 28 pipeline programs.
Analysis
Trial Status
27
clinical trials
Recruiting8 · 30%
Not yet recruiting5 · 19%
Completed5 · 19%
Terminated4 · 15%
Active, not recruiting3 · 11%
Withdrawn1 · 4%
Other1 · 4%
Clinical Trials
Trial Activity
27 trials
Chidamide Maintenance to Prevent Relapse After Allogeneic HSCT in Acute T-Lymphoblastic Leukemia/Lymphoma: A Multicenter Randomized Controlled Trial
Not yet recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 3·NCT07774377·132 enrolled
A Multicenter, Open-Label, Non-Randomized, Single-Arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Preclinical·NCT07678307·18 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)